What question did this study set out to answer?

February 2, 2026Open Access

Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification

Puntos clave

To evaluate the short-term anatomical and durability outcomes of intravitreal aflibercept 8 mg in eyes previously treated with aflibercept 2 mg for neovascular age-related macular degeneration (nAMD).
Conducted a real-world study on patients treated with intravitreal afl8.
Evaluated anatomical and durability outcomes post-treatment.
Utilized AI-based biomarker quantification for data analysis.
Noted potential short-term benefits of afl8 in enhancing anatomical outcomes.
Demonstrated improved durability in treated eyes.
Highlighted added value from data-driven evaluations.

Resumen

Our real-world study supports the potential short-term benefits of afl8 in improving anatomical and durability outcomes in patients with recurrent nAMD. These findings also highlight the added value of data-driven evaluations. Long-term studies are needed to confirm the effectiveness and durability of afl8 in this population.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo